Skip to content
Study details
Enrolling now

NO During CPB in Neonates to Reduce Risk of AKI

Children's Hospital Medical Center, Cincinnati
NCT IDNCT04216927ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

40

Study length

about 3.5 years

Ages

0.00273790700698851–0.0848751172166437

Locations

1 site in OH

What this study is about

This trial is testing whether giving nitric oxide during cardiopulmonary bypass (CPB) can help prevent acute kidney injury (AKI) in newborns with congenital heart defects who are undergoing surgery. The goal is to see if this treatment reduces the risk of AKI after surgery.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Nitric Oxide
  • 2.Take Oxygen

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

nitric oxide, oxygen

Endpoints

Secondary: Biomarker evidence of AKI - IL-18, Biomarker evidence of AKI - KIM-1, Biomarker evidence of AKI - L-FABP, Biomarker evidence of AKI - NGAL, Biomarker evidence of AKI - urinary nitrite

Body systems

Cardiology / Heart